Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
TECH · Nasdaq · United States · Biological Products, (No Diagnostic Substances)
In shortBIO-TECHNE Corp is profitable, generates cash and holds more cash than debt, with revenue stable (−0.4% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 20.7% | 86/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 15.0% | 80/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 9.0% | 45/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 8.2% | 55/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.55× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.09× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 26.16× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 8.20 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 21.7% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.45× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 7.6% | 83/100 |
| Operating margin volatility | 7.5% | 41/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 2.2% | 29/100 |
|---|---|---|
| EPS growth, 3-year average | -13.0% | 0/100 |
Weight in the score: 10%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,106 | 1,137 | 1,159 | 1,220 | 1,215 |
| Cost of revenue | 349 | 367 | 389 | 429 | 416 |
| Gross profit | 756 | 770 | 770 | 790 | 799 |
| Research & development | 87 | 92 | 97 | 99 | 95 |
| Selling, general & admin | 373 | 378 | 466 | 589 | 452 |
| Operating income | 297 | 299 | 207 | 102 | 252 |
| Interest expense | 11 | 11 | 16 | 8.5 | 9.6 |
| Pre-tax income | 301 | 339 | 186 | 98 | 241 |
| Income tax | 38 | 53 | 18 | 25 | 59 |
| Net income | 272 | 285 | 168 | 73 | 182 |
| Diluted EPS | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
| Diluted shares (millions) | 164 | 162 | 161 | 160 | 157 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of BIO-TECHNE Corp are included in the Investor plan. Try free for 7 days →
8.20 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 24, 2026